These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22897825)

  • 1. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
    Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency.
    Yamashita T; Seino Y; Ogawa A; Ogata K; Fukushima M; Tanaka K; Mizuno K
    J Cardiol; 2010 May; 55(3):377-83. PubMed ID: 20350516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
    Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
    Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy.
    Kouloubinis A; Kaklamanis L; Ziras N; Sofroniadou S; Makaritsis K; Adamopoulos S; Revela I; Athanasiou A; Mavroudis D; Georgoulias V
    Int J Cardiol; 2007 Nov; 122(3):195-201. PubMed ID: 17289172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
    Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
    Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
    Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
    J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
    Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major.
    Delaporta P; Kattamis A; Apostolakou F; Boiu S; Bartzeliotou A; Tsoukas E; Papassotiriou I
    Blood Cells Mol Dis; 2013 Jan; 50(1):20-4. PubMed ID: 23017692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
    Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
    Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
    Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
    Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction.
    Arikan S; Tuzcu A; Gokalp D; Bahceci M; Danis R
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):202-7. PubMed ID: 17547691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
    David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
    Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.